10月15日，施贵宝盘中上涨3.64%，报61.91美元/股，成交额1.07亿美元。
消息面上，市场继续消化公司两项三期研究的积极结果，带动创新管线价值重估。
其中，Admilparant在ALOFT-IPF试验中，60毫克剂量组达到52周用力肺活量主要终点；RayzeBio放射性药物RYZ101三期研究期中分析也达到主要终点，显著改善无进展生存期。公司此前还表示，一例高剂量组患者死亡事件很可能与治疗无关。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.